Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management - Global
- Beta
- 0.70
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
SLIMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
55+175.00%Social Signal Score
Mentions (37)
- Newsfool.com·9h ago·Neutral
Eli Lilly's Obesity Pipeline Is Getting Crowded. That's Great News for Investors Zepbound and Foundayo currently anchor Eli Lilly's obesity lead. Retatrutide and EloraTZP outperformed Zepbound in weight-loss trials, though not yet in head-to-head Phase 3 studies.
View source ↗ - Newsfool.com·1d ago·Neutral
Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy? Novo Nordisk was the first to market with a GLP-1 weight-loss shot, but lost its lead to Eli Lilly. Given the size of the weight-loss market, there's likely to be room for more than one GLP-1 maker.
View source ↗ - Newsmarketbeat.com·4d ago·Negative
Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing Viking Therapeutics NASDAQ: VKTX is preparing for a potential 2029 launch of its obesity drug candidate VK2735 while studying whether patients can maintain weight loss with less frequent injections or a daily oral tablet, CEO Brian Lian said at the Jefferies Global Healthcare Conference in London.
View source ↗ - Newsfool.com·4d ago·Positive
Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway. Viking Therapeutics has four phase 3 obesity trials underway for VK2735. Significant upside exists, but risks and competition remain high.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences ObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.
View source ↗ - Newsprnewswire.com·7d ago·Neutral
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endoc
View source ↗ - Newszacks.com·9d ago·Negative
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.
View source ↗ - Newsglobenewswire.com·10d ago·Negative
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events reported as treatment related -5 of 10 Wegovy subjects (control group) experienced adverse events reported as treatment related (gastrointestinal only, consistent with marketed GLP-1 therapies) …
View source ↗ - Newsmarketbeat.com·13d ago·Negative
Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data Corbus Pharmaceuticals NASDAQ: CRBP has started a Phase 3 study of its cancer drug CRB-701 and expects an exploratory readout from a separate frontline combination study in the first quarter of next year, CEO Yuval Cohen said at the Guggenheim Healthcare Innovation Conference.
View source ↗ - News247wallst.com·24d ago·Negative
Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3 Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, and Amanat Acquisition Corp (Nasdaq: AMAN) (“Amanat”), a publicly traded speci
View source ↗ - News247wallst.com·28d ago·Negative
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28 Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.
View source ↗ - Newsmarketbeat.com·32d ago·Neutral
Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances Rani Therapeutics NASDAQ: RANI outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai.
View source ↗ - Newszacks.com·32d ago·Negative
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
View source ↗ - Newsfool.com·35d ago·Neutral
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. Multiple phase 3 trials for VK2735 are ongoing, with key results expected in 2027 to 2028. The company's future depends on VK2735's clinical success and ongoing pipeline development.
View source ↗ - News247wallst.com·37d ago·Negative
A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the dust.
View source ↗ - Newszacks.com·38d ago·Negative
Viking Therapeutics Starts Phase III Development of Obesity Pill VKTX launches two phase III studies of oral VK2735 for obesity, building on phase II results showing up to 12.2% mean weight loss.
View source ↗ - Newsprnewswire.com·39d ago·Neutral
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the SUNRISE Phase 3 clinical prog
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity -- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --
View source ↗ - Newsprnewswire.com·47d ago·Negative
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine
View source ↗ - Newsbenzinga.com·53d ago·Negative
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss Novo Nordisk A/S (NYSE:NVO) on Wednesday revealed new clinical and real-world data at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, showcasing the efficacy of its next-generation weight-loss treatments.
View source ↗ - Newsmarketbeat.com·60d ago·Positive
Viking's Obesity Edge May Be Staying Power, Not Weight Loss Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.
View source ↗ - Newsglobenewswire.com·60d ago·Negative
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
View source ↗ - News247wallst.com·61d ago·Neutral
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals
View source ↗ - Newsbenzinga.com·61d ago·Negative
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing Viking Therapeutics Inc. (NASDAQ:VKTX) stock surged on Tuesday after the company released positive topline results from its much-anticipated VK2735 maintenance trial.
View source ↗ - News247wallst.com·65d ago·Neutral
Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation? Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.
View source ↗ - Newsglobenewswire.com·67d ago·Negative
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
View source ↗ - News247wallst.com·68d ago·Negative
Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption A landmark trial just proved semaglutide can pull children as young as six below the obesity threshold, yet Wall Street shrugged and the real battle over who pays, who prescribes, and whether society is ready has barely begun.
View source ↗ - Newsmarketbeat.com·68d ago·Positive
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average body mass index of approximately 37 and 71% of participants being female.
View source ↗ - Newsmarketbeat.com·68d ago·Negative
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss Viking Therapeutics NASDAQ: VKTX said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.
View source ↗ - Newsglobenewswire.com·69d ago·Negative
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile Data support CRB-913's potential to establish a new class of oral non-increti
View source ↗ - Newsglobenewswire.com·72d ago·Neutral
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
View source ↗ - Newsglobenewswire.com·82d ago·Negative
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination
View source ↗ - Newsglobenewswire.com·90d ago·Negative
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan -- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
View source ↗ - Newsfool.com·91d ago·Neutral
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.
View source ↗ - Newsmarketbeat.com·98d ago·Neutral
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
View source ↗ - Newsseekingalpha.com·107d ago·Neutral
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion Eli Lilly and Company delivered a monumental Q2 2026, with revenues up 48% to $23 billion, driven by MOUNJARO and ZEPBOUND. I maintain a 'Strong Buy' rating on the company, citing robust double-digit growth in key drugs and successful pipeline expansion, including positive phase 3 retatrutide data. EBGLYSS achieved 131% YoY sales growth and secured a label expansion, offering the only 6-dose annual mainte
View source ↗
Congress trades
No disclosed congressional trades in SLIM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
